BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2015

View Archived Issues

Recent FDA orphan drug designations given to cancer products

Read More

ISA-101 assessed in phase II combination trial with checkpoint inhibitor nivolumab

Read More

Imetelstat shows promise for refractory anemia

Read More

Novel Ras inhibitors from ADT Pharmaceuticals suppress tumor growth in vivo

Read More

Partikula's KULA-101 inhibits multiple immune checkpoint proteins in study

Read More

CytRx selects DK-049 for clinical development next year

Read More

EMA accepts MAA for Gedeon Richter's biosimilar pegfilgrastim

Read More

R-Pharm begins global phase III trial program for olokizumab

Read More

Sucampo acquires R-Tech Ueno

Read More

Treeway and Cedars-Sinai collaborate to advance AAV5-GDNF gene therapy for ALS

Read More

Merck KGaA terminates development of evofosfamide

Read More

Eli Lilly presents clinical results for emibetuzumab

Read More

Gamida Cell discloses results from phase I/II trial of NiCord

Read More

Technique devised for imaging platelets in thrombosis models

Read More

Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the U.S. and E.U.

Read More

Experimental cardiac arrest and resuscitation uses aged animals

Read More

Ignyta initiates pediatric study of entrectinib

Read More

BMS completes acquisition of Cardioxyl Pharmaceuticals

Read More

Tetra Discovery Partners initiates phase I trials of BPN-14770 for Alzheimer's disease

Read More

Pluristem and United Therapeutics end licensing agreement for PLX-PAD

Read More

Purdue Canada acquires Merck & Co.'s ophthalmology franchise under Mundipharma deal

Read More

Mexico approves Dengvaxia, world's first dengue vaccine

Read More

New alliances target neurodegenerative diseases and KCNQ2 epileptic encephalopathy

Read More

Shanghai Fochon Pharmaceutical patents CDK4/6 inhibitors

Read More

Kyung Hee University discloses T-type calcium channel blockers

Read More

Tangrun Pharmaceuticals develops HCV NS5A inhibitors

Read More

Roche acquires Kapa Biosystems to potentiate NGS product offerings

Read More

Bayer Schering Pharma presents MNK1 inhibitors

Read More

GlaxoSmithKline reports CXCR2 antagonists

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing